不同剂型紫杉醇联合卡铂治疗晚期卵巢癌患者的临床疗效及对血清人附睾蛋白4、糖类抗原125和T淋巴细胞亚群水平的影响

Effect of different dosage forms of paclitaxel combined with carboplatin in patients with advanced ovarian cancer and its impact on serum human epididymal protein 4,carbohydrate antigen 125 and T lymphocyte subsets

目的探讨不同剂型紫杉醇联合卡铂治疗晚期卵巢癌患者的临床疗效及对血清人附睾蛋白4(HE4)、糖类抗原125(CA125)和T淋巴细胞亚群水平的影响。方法根据治疗方法的不同将100例晚期卵巢癌患者分为观察组(n=55)和对照组(n=45),观察组患者予以紫杉醇脂质体联合卡铂治疗,对照组患者予以紫杉醇注射液联合卡铂治疗。两组患者均每7天用药1次,21天为1个化疗周期,共治疗6个周期。比较两组患者的临床疗效、不良反应发生情况及治疗前后的血清HE4、CA125及T淋巴细胞亚群水平。结果观察组患者的总有效率为67.27%,与对照组患者的64.44%比较,差异无统计学意义(P﹥0.05)。观察组患者的不良反应总发生率为20.00%,明显低于对照组的46.67%,差异有统计学意义(P﹤0.01)。治疗1个周期、3个周期、6个周期后,观察组患者的血清HE4和CA125水平均低于同时间点对照组患者,差异均有统计学意义(P﹤0.05)。治疗后,两组患者的CD3^(+)、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+)比较,差异均无统计学意义(P﹥0.05)。结论紫杉醇脂质体联合卡铂治疗晚期卵巢癌患者的临床疗效略优于紫杉醇注射液联合卡铂,前者的不良反应较少,安全性更好,且可显著降低患者的血清HE4、CA125水平。

Objective To investigate the effect of different dosage forms of paclitaxel combined with carboplatin in patients with advanced ovarian cancer and its impact on serum levels of human epididymal protein 4(HE4),carbohydrate antigen 125(CA125)and T lymphocyte subsets.Method A total of 100 patients with advanced ovarian cancer were divided into the observation group(n=55)and control group(n=45)according to different treatment regimens.Patients in the observation group were treated with the combination of paclitaxel liposome and carboplatin,and patients in the control group were treated with the combination of paclitaxel injection and carboplatin.The two groups of patients were treated every 7 days and 21 days as one cycle with six cycles.The clinical effect,adverse events,and the levels of serum HE4,CA125,and T lymphocyte subsets before and after treatment were compared between the two groups.Result The total response rate of the observation group was 67.27%,compared with 64.44%of the control group,the difference was not statistically significant(P>0.05).The total incidence of adverse events in the observation group was 20.00%,which was significantly lower than the 46.67%in the control group,and the difference was statistically significant(P<0.01).After one cycle,three cycles,and six cycles of treatment,the serum HE4 and CA125 levels of the observation group were lower than those of the control group simultaneously,the differences were statistically significant(P<0.05).After treatment,there was no statistically significant difference in the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups(P>0.05).Conclusion The clinical efficacy of paclitaxel liposome combined with carboplatin in treating patients with advanced ovarian cancer is slightly better than that of paclitaxel injection combined with carboplatin.The forgoing regimen has fewer adverse events,better safety,and could significantly reduce the serum levels of HE4 and CA125 in patients.